Continuous Glucose Monitoring Market, By Component (Transmitter, Receiver, Sensor, and Insulin pumps), and by End-User (Diagnostics/Clinics, ICUs, and Home Healthcare), Industry Trends, Estimation & Forecast, 2014-2025

pa_user-types

Check Today's Best Price

$3500 Buy Now
The global continuous glucose monitoring market is valued at XX million US$ in 2018 is expected to reach 12,062.1 million US$ by the end of 2026, growing at a CAGR of 22.3% during 2019-2025.
  • Market Overview

    The global continuous glucose monitoring market is valued at XX million US$ in 2018 is expected to reach 12,062.1 million US$ by the end of 2026, growing at a CAGR of 22.3% during 2019-2025.

    Continuous Glucose Monitoring (CGM) is a device used for monitoring blood glucose continually for type I or type II diabetes. Continuous glucose monitor takes reading on set intervals with a small electrode placed under the skin and held in place by an adhesive. A transmitter attached to the electrode sends the information to a monitor. The monitor can be a part of an insulin pump or a separate device, which you might carry in a pocket or purse. Some CGMs send information directly to a smartphone or tablet.

    Continuous Glucose Monitoring Market Value 2017-2026

    Market Driver

    The rising incidence of diabetes is one of the key factor driving the global continuous glucose monitoring market. For instance, according to the American Diabetes Association, in 2015, 30.3 million Americans, or 9.4% of the population, had diabetes. Approximately 1.25 million American children and adults have type 1 diabetes. According to international diabetes federation, in 2017, there were over 12,465,800 cases of diabetes in Brazil. Prevalence of diabetes in adults has increased to 8.7%. According to World Health Organization (WHO), in 2016, almost 10% of adults in China, which is about 110 million people have diabetes. The prevalence of diabetes in China is 10.9%. According to the Indian Council for Medical Research, in 2017, India represents 49% of the world’s diabetes burden, with an estimated 72 million cases, and it is expected to increase by 134 million in 2025. Diabetes prevalence has increased by 64% across India. According to international diabetes federation, in 2017, there were over 1,826,100   cases of diabetes in South Africa. Prevalence of diabetes in adults has increased to 5.4%.

    Market Restraint

    One of the major factors hindering the global continuous glucose monitoring market is undiagnosed population. For instance, it has been estimated that 25%-27% of people with diabetes are unaware of their diabetic condition. According to the Centers for Disease Control and Prevention, more than 70% of diabetic patients reside in developing and under-developed countries. According to Centers for Disease Control and Prevention (CDC), 7.2 million, which is 23.8% of U.S population with diabetes are undiagnosed in 2017.

    Segment Analysis

    Based on Component, the global Continuous Glucose Monitoring market is broadly segmented as Transmitter, Receiver, Sensor, and Insulin pumps. In 2018 Transmitter is the dominant segment, and it accounts for approximately 25% of the market.

    The transmitter of a CGM system is about the size of a quarter and hooks into the sensor and sends real-time glucose information readings wirelessly to a receiver so that the user can view the information. The transmitter is small, flat, and waterproof. It contains a battery that is either permanent (lasting for a fixed lifetime), replaced as needed, or recharged periodically. In the cases of sensors embedded into the skin, the transmitter is worn over the CGM sensor. Transmitters of the continuous glucose monitoring system are constantly improved design-wise and its life-cycle. The technological advancement is mainly due to the new sensors being launched and approved by the FDA.

    The recent transmitters have become more user-friendly with its additional feature. For example, Senseonics Eversense CGM System has a smart transmitter worn on the arm, directly over the sensor, wirelessly powers the data transfer from the sensor and can last for months. It is removable, rechargeable, water-resistant and sends alerts and notifications to the mobile device and also as on-body vibe alerts from smart transmitter even when a mobile device is not nearby during highs and lows. Medtronic’s Guardian Connect Smart CGM has a Bluetooth transmitter. The Dexcom G4 Platinum system’s transmitter is a reusable device and wirelessly sends the sensor’s glucose information to the receiver.

    Continuous Glucose Monitoring Market - by Component

    The sensor has shown significant growth in 2018, and it is expected to grow in the forecasting years, due to the regulatory approval for continues glucose monitoring with sensors. For instance, on June 21, 2018, Senseonics Holdings, Inc., have received the U.S. Food and Drug Administration approval for Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. It is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to 90 days. Moreover, in February 26, 2018, Medtronic, have received FDA approval for new arm indication the Guardian Sensor 3, the company’s most accurate continuous glucose monitoring system and the only sensor approved in the U.S. to help control automated insulin delivery for patient with diabetes via its hybrid closed-loop system, the MiniMed 670G system.

    Regional Analysis

    The global Continuous Glucose Monitoring market is segmented into North America, Europe, Asia-Pacific, South America, Middle East & Africa.

    North America is dominating the global Continuous Glucose Monitoring market, due to the increasing incidence of diabetes in the U.S. For instance, according to American Diabetes Association, in 2015, 30.3 million Americans, or 9.4% of the population had diabetes. According to the American Diabetes Association, in 2015, 84.1 million age 18 and older in Americans had prediabetes. Diabetes was the 7th leading cause of death in the United States in 2015. According to the Centers for Disease Control and Prevention (CDC), More than 100 million U.S. adults had diabetes or prediabetes in 2017.

    The increase in regulatory approval for continuous glucose monitoring components is one of the key factor driving the global continuous glucose monitoring market. For instance, in March 2018, Medtronic have received FDA approval for its Guardian Connect mobile Continuous Glucose Monitor (CGM), along with the paired Guardian Connect App for Apple iOS devices. The new mobile CGM is approved for 14-75 year-olds, includes the more accurate Guardian Sensor 3, and is approved for both arm and abdomen wear up to seven days. It has a two-hour warmup and requires two fingerstick calibrations per day, with occasional diagnostic calibrations required.

    The North America Continuous Glucose Monitoring market size was XX million USD in 2018, and it will be 5,473.3 million USD in 2026, with a CAGR 25.0% from 2019 to 2026.

    Europe is the second largest market for Continuous Glucose Monitoring in 2018, due to the increase in cases of diabetes. For instance, according to the National Institute for Health and care excellence around 400,000 adults in the UK are affected by type 1 diabetes, and around 27,000 children and young people have either type 1 or type 2 diabetes in 2018. According to Centers for Disease Control and Prevention (CDC), 1 in every 430,530 people under the age of 19 has Type 1 diabetes in 2017. According to CDC, approximately 7% of France’s adult population, which is 45 million have diabetes in 2017. According to international diabetes federation, in 2017, there were over 7,476,800   cases of diabetes in Germany. Prevalence of diabetes in adults has increased to 12.2%.

    Competitive Analysis

    The major players include Medtronic Plc, Dexcom, Roche, GlySens Incorporated, Insulet Corporation, Senseonics Incorporated, Abbott Laboratories, Echo Therapeutics, Inc., AgaMatrix Holdings LLC, and Others.

    The strategic agreement between companies for the distribution of continuous glucose monitoring (CGM) system is driving the global continuous glucose monitoring market. For instance, on February 3, 2019, Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, have extended its distribution agreement with Roche Diabetes Care. The agreement is extended to 31 January 2021. Under the extended agreement, Roche will continue its role as Senseonics exclusive distributor in Brazil, and other countries around the globe. Moreover, in May 2018, Terumo Corporation signed an agreement with U.S.-based DexCom, Inc. to distribute the company’s Continuous Glucose Monitoring (CGM) devices exclusively in Japan. Additionally, in August 2016, Hunan China Sun Pharmaceutical Machinery entered into a strategic agreement with Glucovation, Inc. The two companies have agreed to create a Joint Venture in China’s Hunan Province for the development, manufacturing, and distribution of Glucovation’s Continuous Glucose Monitoring System (CGM).

    Global Allergen immunotherapy Market

    • Consumption by Regions
      • North America
      • Europe
      • South America
      • Asia Pacific
      • The Middle East and Africa
    • Segment by Type
      • Transmitter
      • Receiver
      • Sensor
      • Insulin pumps
    • Segment by End User
      • Diagnostics/Clinics
      • ICUs
      • Home Healthcare
    keyboard_arrow_up
  • Table of Content

    1. Market Introduction
    1.1. Executive Summary
    1.2. Market Definition
    1.3. Market Scope

    2. Research Methodology
    2.1. Primary Research
    2.2. Research Methodology
    2.3. Assumptions & Exclusions
    2.4. Secondary data sources

    3. Continuous Glucose Monitoring Market Overview
    3.1. Report Segmentation & Scope
    3.2. Key Market Trend
    3.3. Drivers
    3.3.1. The rising incidence of diabetes
    3.3.2. Increasing pipeline devices of continuous glucose monitoring
    3.4. Restraints
    3.4.1. Increasing undiagnosed population
    3.5. Opportunity
    3.5.1. The high adoption rate of CGMS in home healthcare and ICUs
    3.6. Porter’s Five Forces Analysis
    3.6.1. Porter’s Five Forces Analysis
    3.7. Market Share Analysis

    4. Component Overview
    4.1. Introduction
    4.1.1. Market Size & Forecast
    4.2. Transmitter
    4.2.1. Market Size & Forecast
    4.3. Receiver
    4.3.1. Market Size & Forecast
    4.4. Sensor
    4.4.1. Market Size & Forecast
    4.5. Insulin Pumps
    4.5.1. Market Size & Forecast

    5. End-User Overview
    5.1. Introduction
    5.1.1. Market Size & Forecast
    5.2. Diagnostics/Clinics
    5.2.1. Market Size & Forecast
    5.3. ICUs
    5.3.1. Market Size & Forecast
    5.4. Home Healthcare
    5.4.1. Market Size & Forecast

    6. Continuous Glucose Monitoring Market Regional Overview
    6.1. Introduction
    6.1.1. Market Size & Forecast
    6.2. North America Continuous Glucose Monitoring Market
    6.2.1. North America Market Size & Forecast, By Country
    6.2.2. North America Market Size & Forecast, By Component
    6.2.3. North America Market Size & Forecast, By End-User
    6.2.4. The U.S.
    6.2.4.1. Market Size and Forecast
    6.2.5. Canada
    6.2.5.1. Market Size and Forecast
    6.2.6. Mexico
    6.2.6.1. Market Size and Forecast
    6.3. Europe Continuous Glucose Monitoring Market
    6.3.1. Europe Market Size & Forecast, By Country
    6.3.2. Europe Market Size & Forecast, By Component
    6.3.3. Europe Market Size & Forecast, By End-User
    6.3.4. Germany
    6.3.4.1. Market Size and Forecast
    6.3.5. France
    6.3.5.1. Market Size and Forecast
    6.3.6. UK
    6.3.6.1. Market Size and Forecast
    6.3.7. Italy
    6.3.7.1. Market Size and Forecast
    6.3.8. Spain
    6.3.8.1. Market Size and Forecast
    6.3.9. Rest of Europe
    6.3.9.1. Market Size and Forecast
    6.4. Asia-Pacific Continuous Glucose Monitoring Market
    6.4.1. Asia-Pacific Market Size & Forecast, By Country
    6.4.2. Asia-Pacific Market Size & Forecast, By Component
    6.4.3. Asia-Pacific Market Size & Forecast, By End-User
    6.4.4. Japan
    6.4.4.1. Market Size and Forecast
    6.4.5. China
    6.4.5.1. Market Size and Forecast
    6.4.6. Australia
    6.4.6.1. Market Size and Forecast
    6.4.7. India
    6.4.7.1. Market Size and Forecast
    6.4.8. South Korea
    6.4.8.1. Market Size and Forecast
    6.4.9. Rest of Asia-Pacific
    6.4.9.1. Market Size and Forecast
    6.5. Rest of the World Continuous Glucose Monitoring Market
    6.5.1. Rest of the World Market Size & Forecast, By Country
    6.5.2. Rest of the World Market Size & Forecast, By Component
    6.5.3. Rest of the World Market Size & Forecast, By End-User
    6.5.4. South America
    6.5.4.1. Market Size and Forecast
    6.5.5. Middle East
    6.5.5.1. Market Size and Forecast
    6.5.6. Africa
    6.5.6.1. Market Size and Forecast

    7. Company Profile
    7.1. Medtronic Plc
    7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.1.2. Medtronic Plc Product Category, Application, and Specification
    7.1.3. Medtronic Plc Financial Performance (2016-2018)
    7.1.4. Main Business/Business Overview
    7.2. Dexcom
    7.3. Roche
    7.4. GlySens Incorporated
    7.5. Insulet Corporation
    7.6. Senseonics Incorporated
    7.7. Abbott Laboratories
    7.8. Echo Therapeutics, Inc.
    7.9. AgaMatrix Holdings LLC
    7.10. Others

    keyboard_arrow_up
    • The following manufacturers are covered:
      • Medtronic Plc
      • Dexcom
      • Roche
      • GlySens Incorporated
      • Insulet Corporation
      • Senseonics Incorporated
      • Abbott Laboratories
      • Echo Therapeutics, Inc.
      • AgaMatrix Holdings LLC
      • Others
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS

SHARE YOUR CART